<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39452697</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-0817</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Pathogens (Basel, Switzerland)</Title><ISOAbbreviation>Pathogens</ISOAbbreviation></Journal><ArticleTitle>Advances in the Search for SARS-CoV-2 M<sup>pro</sup> and PL<sup>pro</sup> Inhibitors.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">825</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pathogens13100825</ELocationID><Abstract><AbstractText>SARS-CoV-2 is a spherical, positive-sense, single-stranded RNA virus with a large genome, responsible for encoding both structural proteins, vital for the viral particle's architecture, and non-structural proteins, critical for the virus's replication cycle. Among the non-structural proteins, two cysteine proteases emerge as promising molecular targets for the design of new antiviral compounds. The main protease (M<sup>pro</sup>) is a homodimeric enzyme that plays a pivotal role in the formation of the viral replication-transcription complex, associated with the papain-like protease (PL<sup>pro</sup>), a cysteine protease that modulates host immune signaling by reversing post-translational modifications of ubiquitin and interferon-stimulated gene 15 (ISG15) in host cells. Due to the importance of these molecular targets for the design and development of novel anti-SARS-CoV-2 drugs, the purpose of this review is to address aspects related to the structure, mechanism of action and strategies for the design of inhibitors capable of targeting the M<sup>pro</sup> and PL<sup>pro</sup>. Examples of covalent and non-covalent inhibitors that are currently being evaluated in preclinical and clinical studies or already approved for therapy will be also discussed to show the advances in medicinal chemistry in the search for new molecules to treat COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Diogo</LastName><ForeName>Marcel Arruda</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-5725-7323</Identifier><AffiliationInfo><Affiliation>Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabral</LastName><ForeName>Augusto Gomes Teixeira</ForeName><Initials>AGT</Initials><AffiliationInfo><Affiliation>Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Oliveira</LastName><ForeName>Renata Barbosa</ForeName><Initials>RB</Initials><Identifier Source="ORCID">0000-0001-5884-2567</Identifier><AffiliationInfo><Affiliation>Departamento de Produtos Farmacêuticos, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pathogens</MedlineTA><NlmUniqueID>101596317</NlmUniqueID><ISSNLinking>2076-0817</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Mpro</Keyword><Keyword MajorTopicYN="N">PLpro</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cysteine protease</Keyword><Keyword MajorTopicYN="N">inhibitors</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39452697</ArticleId><ArticleId IdType="pmc">PMC11510351</ArticleId><ArticleId IdType="doi">10.3390/pathogens13100825</ArticleId><ArticleId IdType="pii">pathogens13100825</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Onyeaka H., Anumudu C.K., Al-Sharify Z.T., Egele-Godswill E., Mbaegbu P. COVID-19 pandemic: A review of the global lockdown and its far-reaching effects. Sci. Prog. 2021;104:1–18. doi: 10.1177/00368504211019854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00368504211019854</ArticleId><ArticleId IdType="pmc">PMC10454957</ArticleId><ArticleId IdType="pubmed">34061685</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y., Wang Y., Wang M., Zhou L., Shi J., Cao J., Wang D. The origins of COVID-19 pandemic: A brief overview. Transbound. Emerg. Dis. 2022;69:3181–3197. doi: 10.1111/tbed.14732.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tbed.14732</ArticleId><ArticleId IdType="pmc">PMC9874793</ArticleId><ArticleId IdType="pubmed">36218169</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  . Number of COVID-19 Cases Reported to WHO. WHO; Geneva, Switzerland: 2024.  [(accessed on 15 July 2024)].  Available online:  https://data.who.int/dashboards/covid19/cases.</Citation></Reference><Reference><Citation>Ke Z., Oton J., Qu K., Cortese M., Zila V., Mckeane L., Nakane T., Zivanov J., Neufeldt C.J., Cerikan B. Structures and distributions of SARS-CoV-2 spike proteins on intact virions. Nature. 2020;588:498–502. doi: 10.1038/s41586-020-2665-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2665-2</ArticleId><ArticleId IdType="pmc">PMC7116492</ArticleId><ArticleId IdType="pubmed">32805734</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardenbrook N.J., Zhang P. A structural view of the SARS-CoV-2 virus and its assembly. Curr. Opin. Virol. 2022;52:123–134. doi: 10.1016/j.coviro.2021.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2021.11.011</ArticleId><ArticleId IdType="pmc">PMC8642146</ArticleId><ArticleId IdType="pubmed">34915287</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T., Zhang Z., Wu Z. Molecular Architecture of the SARS-CoV-2 Virus. Cell. 2020;183:730–738. doi: 10.1016/j.cell.2020.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.018</ArticleId><ArticleId IdType="pmc">PMC7474903</ArticleId><ArticleId IdType="pubmed">32979942</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2021;23:3–20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat. Rev. Microbiol. 2021;19:685–700. doi: 10.1038/s41579-021-00630-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00630-8</ArticleId><ArticleId IdType="pmc">PMC8447893</ArticleId><ArticleId IdType="pubmed">34535791</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusev E., Sarapultsev A., Solomatina L., Chereshnev V. SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19. Int. J. Mol. Sci. 2022;23:1716. doi: 10.3390/ijms23031716.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23031716</ArticleId><ArticleId IdType="pmc">PMC8835786</ArticleId><ArticleId IdType="pubmed">35163638</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan W., Zheng Y., Zeng X., He B., Cheng W. Structural biology of SARS-CoV-2: Open the door for novel therapies. Signal Transduct. Target. Ther. 2022;7:26. doi: 10.1038/s41392-022-00884-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00884-5</ArticleId><ArticleId IdType="pmc">PMC8793099</ArticleId><ArticleId IdType="pubmed">35087058</ArticleId></ArticleIdList></Reference><Reference><Citation>V’kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. 2020;19:155–170. doi: 10.1038/s41579-020-00468-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId><ArticleId IdType="pmc">PMC7592455</ArticleId><ArticleId IdType="pubmed">33116300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravi V., Saxena S., Panda P.S. Basic virology of SARS-CoV 2. Indian J. Med. Microbiol. 2022;40:182–186. doi: 10.1016/j.ijmmb.2022.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmmb.2022.02.005</ArticleId><ArticleId IdType="pmc">PMC8919811</ArticleId><ArticleId IdType="pubmed">35300895</ArticleId></ArticleIdList></Reference><Reference><Citation>Sui L., Zhao Y., Wang W., Wu P., Wang Z., Yu Y., Hou Z., Tan G., Liu Q. SARS-CoV-2 Membrane Protein Inhibits Type I Interferon Production Through Ubiquitin-Mediated Degradation of TBK1. Front. Immunol. 2021;12:662989. doi: 10.3389/fimmu.2021.662989.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.662989</ArticleId><ArticleId IdType="pmc">PMC8168463</ArticleId><ArticleId IdType="pubmed">34084167</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakavandi S., Zare I., Vaezjalali M., Dadashi M., Azarian M., Akbari A., Farani M.R., Zalpoor H., Hajikhani B. Structural and non-structural proteins in SARS-CoV-2: Potential aspects to COVID-19 treatment or prevention of progression of related diseases. Cell Commun. Signal. 2023;21:110. doi: 10.1186/s12964-023-01104-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-023-01104-5</ArticleId><ArticleId IdType="pmc">PMC10183699</ArticleId><ArticleId IdType="pubmed">37189112</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai C., Zhong Q., Gao G.F. Overview of SARS-CoV-2 genome-encoded proteins. Sci. China Life Sci. 2021;65:280–294. doi: 10.1007/s11427-021-1964-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11427-021-1964-4</ArticleId><ArticleId IdType="pmc">PMC8362648</ArticleId><ArticleId IdType="pubmed">34387838</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Guo H., Zhou P., Shi Z. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2020;19:141–154. doi: 10.1038/s41579-020-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghuvamsi P.V., Tulsian N.K., Samsudin F., Qian X., Purushotorman K., Yue G., Kozma M.M., Hwa W.Y., Lescar J., Bond P.J. SARS-CoV-2 S protein: ACE2 interaction reveals novel allosteric targets. Elife. 2021;10:e63646. doi: 10.7554/eLife.63646.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.63646</ArticleId><ArticleId IdType="pmc">PMC7932696</ArticleId><ArticleId IdType="pubmed">33554856</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Vanstreels E., Jansen S., Daelemans D. Cellular host factors for SARS-CoV-2 infection. Nat. Microbiol. 2021;6:1219–1232. doi: 10.1038/s41564-021-00958-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00958-0</ArticleId><ArticleId IdType="pubmed">34471255</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., Yin W., Jiang Y., Xu H.E. Structure genomics of SARS-CoV-2 and its Omicron variant: Drug design templates for COVID-19. Acta Pharmacol. Sin. 2022;43:3021–3033. doi: 10.1038/s41401-021-00851-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-021-00851-w</ArticleId><ArticleId IdType="pmc">PMC8771608</ArticleId><ArticleId IdType="pubmed">35058587</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark L.K., Green T.J., Petit C.M. Structure of Nonstructural Protein 1 from SARS-CoV-2. J. Virol. 2021;95:10–1128. doi: 10.1128/JVI.02019-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02019-20</ArticleId><ArticleId IdType="pmc">PMC7851544</ArticleId><ArticleId IdType="pubmed">33234675</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam M.J., Islam N.A.N., Alom M.S., Kabir M., Halim M.A. A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites. Immunobiology. 2023;228:152302. doi: 10.1016/j.imbio.2022.152302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2022.152302</ArticleId><ArticleId IdType="pmc">PMC9663145</ArticleId><ArticleId IdType="pubmed">36434912</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Kirkpatrick J., Zur Lage S., Carlomagno T. Structural insights into the activity regulation of full-length non-structural protein 1 from SARS-CoV-2. Structure. 2023;31:128–137. doi: 10.1016/j.str.2022.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2022.12.006</ArticleId><ArticleId IdType="pmc">PMC9817231</ArticleId><ArticleId IdType="pubmed">36610391</ArticleId></ArticleIdList></Reference><Reference><Citation>Calleja D.J., Lessene G., Komander D. Inhibitors of SARS-CoV-2 PLpro. Front. Chem. 2022;10:876212. doi: 10.3389/fchem.2022.876212.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2022.876212</ArticleId><ArticleId IdType="pmc">PMC9086436</ArticleId><ArticleId IdType="pubmed">35559224</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan V., Brognaro H., Prabhu P.R., de Souza E.E., Günther S., Reinke P.Y.A., Lane T.J., Ginn H., Han H., Ewert W. Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease. Commun. Biol. 2022;5:805. doi: 10.1038/s42003-022-03737-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-03737-7</ArticleId><ArticleId IdType="pmc">PMC9366811</ArticleId><ArticleId IdType="pubmed">35953531</ArticleId></ArticleIdList></Reference><Reference><Citation>Costanzi E., Kuzikov M., Esposito F., Albani S., Demitri N., Giabbai B., Camasta M., Tramontano E., Rossetti G., Zaliani A., et al. Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L. Int. J. Mol. Sci. 2021;22:11779. doi: 10.3390/ijms222111779.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222111779</ArticleId><ArticleId IdType="pmc">PMC8583849</ArticleId><ArticleId IdType="pubmed">34769210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt P.R., Scaiola A., Loughran G., Leibundgut M., Kratzel A., Meurs R., Dreos R., O’connor K.M., Mcmillan A., Bode J.W. Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome. Science. 2021;372:1306–1313. doi: 10.1126/science.abf3546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf3546</ArticleId><ArticleId IdType="pmc">PMC8168617</ArticleId><ArticleId IdType="pubmed">34029205</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone B., Urakova N., Snijder E.J., Campbell E.A. Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell Biol. 2021;23:21–39. doi: 10.1038/s41580-021-00432-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00432-z</ArticleId><ArticleId IdType="pmc">PMC8613731</ArticleId><ArticleId IdType="pubmed">34824452</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirtipal N., Bharadwaj S., Kang S.G. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infect. Genet. Evol. 2020;85:104502. doi: 10.1016/j.meegid.2020.104502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2020.104502</ArticleId><ArticleId IdType="pmc">PMC7425554</ArticleId><ArticleId IdType="pubmed">32798769</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge X., Zhou H., Shen F., Yang G., Zhang Y., Zhang X., Li H. SARS-CoV-2 subgenomic RNA: Formation process and rapid molecular diagnostic methods. Clin. Chem. Lab. Med. CCLM. 2023;62:1019–1028. doi: 10.1515/cclm-2023-0846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2023-0846</ArticleId><ArticleId IdType="pubmed">38000044</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Z., Cao Y., Liu W., Li J. The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation. Viruses. 2021;13:1115. doi: 10.3390/v13061115.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13061115</ArticleId><ArticleId IdType="pmc">PMC8227405</ArticleId><ArticleId IdType="pubmed">34200602</ArticleId></ArticleIdList></Reference><Reference><Citation>Su H., Xu Y., Jiang H. Drug discovery and development targeting the life cycle of SARS-CoV-2. Fundam. Res. 2021;1:51–165. doi: 10.1016/j.fmre.2021.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fmre.2021.01.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzato M., Baraldi C., Sopetto G.B., Finozzi D., Gentile C., Gentile M.D., Marconi R., Paladino D., Raoss A., Riedmiller I. SARS-CoV-2 and the Host Cell: A tale of interactions. Front. Virol. 2022;1:815388. doi: 10.3389/fviro.2021.815388.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fviro.2021.815388</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Zhao Y.G., Zhang H. Endomembrane remodeling in SARS-CoV-2 infection. Cell Insight. 2022;1:100031. doi: 10.1016/j.cellin.2022.100031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellin.2022.100031</ArticleId><ArticleId IdType="pmc">PMC9112566</ArticleId><ArticleId IdType="pubmed">37193051</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Zheng Q., Sun L., Ji M., Li Y., Deng H., Zhang H. ORF3a of SARS-CoV-2 promotes lysosomal exocytosis-mediated viral egress. Dev. Cell. 2021;56:3250–3263. doi: 10.1016/j.devcel.2021.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2021.10.006</ArticleId><ArticleId IdType="pmc">PMC8502680</ArticleId><ArticleId IdType="pubmed">34706264</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S., Dixit R., Pandey K.C. Cysteine Proteases: Modes of activation and future prospects as pharmacological targets. Front. Pharmacol. 2016;7:107. doi: 10.3389/fphar.2016.00107.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2016.00107</ArticleId><ArticleId IdType="pmc">PMC4842899</ArticleId><ArticleId IdType="pubmed">27199750</ArticleId></ArticleIdList></Reference><Reference><Citation>Barchielli G., Capperucci A., Tanini D. Therapeutic cysteine protease inhibitors: A patent review (2018-present) Expert Opin. Ther. Pat. 2024;34:17–49. doi: 10.1080/13543776.2024.2327299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543776.2024.2327299</ArticleId><ArticleId IdType="pubmed">38445468</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang N., Matthew M.A., Yao C. Roles of Cysteine Proteases in Biology and Pathogenesis of Parasites. Microorganisms. 2023;11:1397. doi: 10.3390/microorganisms11061397.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11061397</ArticleId><ArticleId IdType="pmc">PMC10300726</ArticleId><ArticleId IdType="pubmed">37374899</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah F., Mukherjee P., Desai P., Avery M. Computational Approaches for the Discovery of Cysteine Protease Inhibitors Against Malaria and SARS. Curr. Comput. Aided-Drug Des. 2010;6:1–23. doi: 10.2174/157340910790980142.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157340910790980142</ArticleId><ArticleId IdType="pubmed">20370692</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawlings N.D., Barrett A.J., Thomas P.D., Huang X., Bateman A., Finn R.D. The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database. Nucleic Acids Res. 2017;46:624–632. doi: 10.1093/nar/gkx1134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1134</ArticleId><ArticleId IdType="pmc">PMC5753285</ArticleId><ArticleId IdType="pubmed">29145643</ArticleId></ArticleIdList></Reference><Reference><Citation>Sajid M., Mckerrow J.H. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. 2002;120:1–21. doi: 10.1016/S0166-6851(01)00438-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-6851(01)00438-8</ArticleId><ArticleId IdType="pubmed">11849701</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolau I., Hădade N.D., Matache M., Funeriu D.P. Synthetic Approaches of Epoxysuccinate Chemical Probes. Chembiochem. 2023;24:e202300157. doi: 10.1002/cbic.202300157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.202300157</ArticleId><ArticleId IdType="pubmed">37096389</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy M., Rawat A., Kaushik S., Jyoti A., Srivastava V.K. Endogenous cysteine protease inhibitors in upmost pathogenic parasitic protozoa. Microbiol. Res. 2022;261:127061. doi: 10.1016/j.micres.2022.127061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micres.2022.127061</ArticleId><ArticleId IdType="pubmed">35605309</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer C., Feys J.R. SARS-CoV-2 Mpro Inhibitors: Achieved diversity, developing resistance and future strategies. Future Pharmacol. 2023;3:80–107. doi: 10.3390/futurepharmacol3010006.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/futurepharmacol3010006</ArticleId></ArticleIdList></Reference><Reference><Citation>Siklos M., Benaissa M., Thatcher G.R.J. Cysteine proteases as therapeutic targets: Does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta Pharm. Sin. B. 2015;5:506–519. doi: 10.1016/j.apsb.2015.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2015.08.001</ArticleId><ArticleId IdType="pmc">PMC4675809</ArticleId><ArticleId IdType="pubmed">26713267</ArticleId></ArticleIdList></Reference><Reference><Citation>Tacias-Pascacio V.G., Morellon-Sterling R., Castañeda-Valbuena D., Berenguer-Murcia Á., Kamli M.R., Tavano O., Fernandez-Lafuente R. Immobilization of papain: A review. Int. J. Biol. Macromol. 2021;188:94–113. doi: 10.1016/j.ijbiomac.2021.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2021.08.016</ArticleId><ArticleId IdType="pubmed">34375660</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X.H., Zhang X., Lu Z.H., Zhu Y.S., Wang T. Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection. Biomed. Pharmacother. 2021;133:111035. doi: 10.1016/j.biopha.2020.111035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.111035</ArticleId><ArticleId IdType="pmc">PMC7671653</ArticleId><ArticleId IdType="pubmed">33254013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullrich S., Nitsche C. SARS-CoV-2 Papain-Like Protease: Structure, function and inhibition. Chembiochem. 2022;23:e202200327. doi: 10.1002/cbic.202200327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.202200327</ArticleId><ArticleId IdType="pmc">PMC9538446</ArticleId><ArticleId IdType="pubmed">35993805</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Yang J. A review of the latest research on Mpro targeting SARS-COV inhibitors. Rsc Med. Chem. 2021;12:1026–1036. doi: 10.1039/D1MD00066G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1MD00066G</ArticleId><ArticleId IdType="pmc">PMC8292989</ArticleId><ArticleId IdType="pubmed">34355175</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonopoulou I., Sapountzaki E., Rova U., Christakopoulos P. Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds. Comput. Struct. Biotechnol. J. 2022;20:1306–1344. doi: 10.1016/j.csbj.2022.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2022.03.009</ArticleId><ArticleId IdType="pmc">PMC8920478</ArticleId><ArticleId IdType="pubmed">35308802</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Q., Xiong Y., Zhu G.-H., Zhang Y.-N., Zhang Y.-W., Huang P., Ge G.-B. The SARS-CoV-2 main protease (Mpro): Structure, function, and emerging therapies for COVID-19. Medcomm. 2022;3:e151. doi: 10.1002/mco2.151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.151</ArticleId><ArticleId IdType="pmc">PMC9283855</ArticleId><ArticleId IdType="pubmed">35845352</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui W., Yang K., Yang H. Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19. Front. Mol. Biosci. 2020;7:616341. doi: 10.3389/fmolb.2020.616341.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.616341</ArticleId><ArticleId IdType="pmc">PMC7746807</ArticleId><ArticleId IdType="pubmed">33344509</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L., Peng C. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289–293. doi: 10.1038/s41586-020-2223-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2223-y</ArticleId><ArticleId IdType="pubmed">32272481</ArticleId></ArticleIdList></Reference><Reference><Citation>Mengist H.M., Dilnessa T., Jin T. Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease. Front. Chem. 2021;9:622898. doi: 10.3389/fchem.2021.622898.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2021.622898</ArticleId><ArticleId IdType="pmc">PMC8056153</ArticleId><ArticleId IdType="pubmed">33889562</ArticleId></ArticleIdList></Reference><Reference><Citation>Nashed N.T., Aniana A., Ghirlando R., Chiliveri S.C., Louis J.M. Modulation of the monomer-dimer equilibrium and catalytic activity of SARS-CoV-2 main protease by a transition-state analog inhibitor. Commun. Biol. 2022;5:160. doi: 10.1038/s42003-022-03084-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-03084-7</ArticleId><ArticleId IdType="pmc">PMC8888643</ArticleId><ArticleId IdType="pubmed">35233052</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S., Rox K., Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science. 2020;368:409–412. doi: 10.1126/science.abb3405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3405</ArticleId><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee R., Perera L., Tillekeratne L.M.V. Potential SARS-CoV-2 main protease inhibitors. Drug Discov. Today. 2021;26:804–816. doi: 10.1016/j.drudis.2020.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2020.12.005</ArticleId><ArticleId IdType="pmc">PMC7724992</ArticleId><ArticleId IdType="pubmed">33309533</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbah D.A., Hajjo R., Bardaweel S.K., Zhong H.A. An Updated Review on SARS-CoV-2 Main Proteinase (Mpro): Protein structure and small-molecule inhibitors. Curr. Top. Med. Chem. 2021;21:442–460. doi: 10.2174/1568026620666201207095117.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026620666201207095117</ArticleId><ArticleId IdType="pubmed">33292134</ArticleId></ArticleIdList></Reference><Reference><Citation>Arutyunova E., Khan M.B., Fischer C., Lu J., Lamer T., Vuong W., Van Belkum M.J., Mckay R.T., Tyrrell D.L., Vederas J.C. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 Mpro Dimer. J. Mol. Biol. 2021;433:167003. doi: 10.1016/j.jmb.2021.167003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2021.167003</ArticleId><ArticleId IdType="pmc">PMC8061786</ArticleId><ArticleId IdType="pubmed">33895266</ArticleId></ArticleIdList></Reference><Reference><Citation>Paciaroni A., Libera V., Ripanti F., Orecchini A., Petrillo C., Francisci D., Schiaroli E., Sabbatini S., Gidari A., Bianconi E. Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir. Int. J. Mol. Sci. 2023;24:6062. doi: 10.3390/ijms24076062.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24076062</ArticleId><ArticleId IdType="pmc">PMC10093836</ArticleId><ArticleId IdType="pubmed">37047038</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., Li J., Liu W., Yang Y., Zhang M., Ye Y., Zhu W., Zhou C., Zhai H., Xu Z. The S1′–S3′ Pocket of the SARS-CoV-2 Main Protease Is Critical for Substrate Selectivity and Can Be Targeted with Covalent Inhibitors. Angew. Chem. Int. Ed. 2023;62:e202309657. doi: 10.1002/anie.202309657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202309657</ArticleId><ArticleId IdType="pubmed">37609788</ArticleId></ArticleIdList></Reference><Reference><Citation>Kneller D.W., Li H., Galanie S., Phillips G., Labbé A., Weiss K.L., Zhang Q., Arnould M.A., Clyde A., Ma H. Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease. J. Med. Chem. 2021;64:17366–17383. doi: 10.1021/acs.jmedchem.1c01475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c01475</ArticleId><ArticleId IdType="pmc">PMC8565456</ArticleId><ArticleId IdType="pubmed">34705466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Zhang H., Lin Q., Lyu J., Lu L., Chen H., Zhang X., Zhang Y., Chen K. Progress on SARS-CoV-2 3CLpro Inhibitors: Inspiration from SARS-CoV 3CLpro peptidomimetics and small-molecule anti-inflammatory compounds. Drug Des. Dev. Ther. 2022;16:1067–1082. doi: 10.2147/DDDT.S359009.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S359009</ArticleId><ArticleId IdType="pmc">PMC9015912</ArticleId><ArticleId IdType="pubmed">35450403</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen D.R., Allerton C.M.N., Anderson A.S., Aschenbrenner L., Avery M., Berritt S., Boras B., Cardin R.D., Carlo A., Coffman K.J. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586–1593. doi: 10.1126/science.abl4784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl4784</ArticleId><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference><Reference><Citation>Citarella A., Scala A., Piperno A., Micale N. SARS-CoV-2 Mpro: A potential target for peptidomimetics and small-molecule inhibitors. Biomolecules. 2021;11:607. doi: 10.3390/biom11040607.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom11040607</ArticleId><ArticleId IdType="pmc">PMC8073203</ArticleId><ArticleId IdType="pubmed">33921886</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes H.S., Sousa S.F., Cerqueira N.M.F.S.A. New insights into the catalytic mechanism of the SARS-CoV-2 main protease: An oniom QM/MM approach. Mol. Divers. 2021;26:1373–1381. doi: 10.1007/s11030-021-10259-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11030-021-10259-7</ArticleId><ArticleId IdType="pmc">PMC8224256</ArticleId><ArticleId IdType="pubmed">34169450</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Z., Cano K.E., Jia L., Drag M., Huang T.T., Olsen S.K. Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development. Front. Chem. 2022;9:819165. doi: 10.3389/fchem.2021.819165.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2021.819165</ArticleId><ArticleId IdType="pmc">PMC8850931</ArticleId><ArticleId IdType="pubmed">35186898</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Pustovalova Y., Shi W., Gorbatyuk O., Sreeramulu S., Schwalbe H., Hoch J.C., Hao B. Crystal structure of the CoV-Y domain of SARS-CoV-2 nonstructural protein 3. Sci. Rep. 2023;13:2890. doi: 10.1038/s41598-023-30045-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-30045-9</ArticleId><ArticleId IdType="pmc">PMC9938512</ArticleId><ArticleId IdType="pubmed">36801935</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam D., Lorenzo-Leal A.C., Hernández L.R., Bach H. Targeting SARS-CoV-2 Non-Structural Proteins. Int. J. Mol. Sci. 2023;24:13002. doi: 10.3390/ijms241613002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241613002</ArticleId><ArticleId IdType="pmc">PMC10455537</ArticleId><ArticleId IdType="pubmed">37629182</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A., Schulz L., Widera M., Mehdipour A.R., Tascher G. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020;587:657–662. doi: 10.1038/s41586-020-2601-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2601-5</ArticleId><ArticleId IdType="pmc">PMC7116779</ArticleId><ArticleId IdType="pubmed">32726803</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin B., Li Z., Tang K., Wang T., Xie Y., Aumonier S., Wang M., Yuan S., Cui S. Identification of the SARS-unique domain of SARS-CoV-2 as an antiviral target. Nat. Commun. 2023;14:3999. doi: 10.1038/s41467-023-39709-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39709-6</ArticleId><ArticleId IdType="pmc">PMC10326071</ArticleId><ArticleId IdType="pubmed">37414753</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Xue B., Schnicker N.J., Wong L.R., Meyerholz D.K., Perlman S. Nsp3-N interactions are critical for SARS-CoV-2 fitness and virulence. Proc. Natl. Acad. Sci. USA. 2023;120:e2305674120. doi: 10.1073/pnas.2305674120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2305674120</ArticleId><ArticleId IdType="pmc">PMC10400999</ArticleId><ArticleId IdType="pubmed">37487098</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Z., Huang B., Tang J., Liu S., Liu M., Ye Y., Liu Z., Xiong Y., Zhu W., Cao D. The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery. Nat. Commun. 2021;12:488. doi: 10.1038/s41467-020-20718-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20718-8</ArticleId><ArticleId IdType="pmc">PMC7817691</ArticleId><ArticleId IdType="pubmed">33473130</ArticleId></ArticleIdList></Reference><Reference><Citation>Osipiuk J., Azizi S.A., Dvorkin S., Endres M., Jedrzejczak R., Jones K.A., Kang S., Kathayat R.S., Kim Y., Lisnyak V.G., et al. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat. Commun. 2021;12:743. doi: 10.1038/s41467-021-21060-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21060-3</ArticleId><ArticleId IdType="pmc">PMC7854729</ArticleId><ArticleId IdType="pubmed">33531496</ArticleId></ArticleIdList></Reference><Reference><Citation>Klemm T., Ebert G., Calleja D.J., Allison C.C., Richardson L.W., Bernardini J.P., Lu B.G., Kuchel N.W., Grohmann C., Shibata Y. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. Embo J. 2020;39:e106275. doi: 10.15252/embj.2020106275.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2020106275</ArticleId><ArticleId IdType="pmc">PMC7461020</ArticleId><ArticleId IdType="pubmed">32845033</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Du X., Duan Y., Pan X., Sun Y., You T., Han L., Jin Z., Shang W., Yu J. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors. Protein Cell. 2021;12:877–888. doi: 10.1007/s13238-021-00836-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-021-00836-9</ArticleId><ArticleId IdType="pmc">PMC8052528</ArticleId><ArticleId IdType="pubmed">33864621</ArticleId></ArticleIdList></Reference><Reference><Citation>Razali R., Asis H., Budiman C. Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources. Microorganisms. 2021;9:2481. doi: 10.3390/microorganisms9122481.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9122481</ArticleId><ArticleId IdType="pmc">PMC8706127</ArticleId><ArticleId IdType="pubmed">34946083</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanan A., Narwal M., Majowicz S.A., Varricchio C., Toner S.A., Ballatore C., Brancale A., Murakami K.S., Jose J. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. Commun. Biol. 2022;5:169. doi: 10.1038/s42003-022-03090-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-022-03090-9</ArticleId><ArticleId IdType="pmc">PMC8881501</ArticleId><ArticleId IdType="pubmed">35217718</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X., Qin B., Chen P., Zhu K., Hou P., Wojdyla J.A., Wang M., Cui S. Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm. Sin. B. 2021;11:237–245. doi: 10.1016/j.apsb.2020.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2020.08.014</ArticleId><ArticleId IdType="pmc">PMC7467110</ArticleId><ArticleId IdType="pubmed">32895623</ArticleId></ArticleIdList></Reference><Reference><Citation>Sencanski M., Perovic V., Milicevic J., Todorovic T., Prodanovic R., Veljkovic V., Paessler S., Glisic S. Identification of SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors Using Combined Computational Approach. Chemistryopen. 2022;11:e202100248. doi: 10.1002/open.202100248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/open.202100248</ArticleId><ArticleId IdType="pmc">PMC8805381</ArticleId><ArticleId IdType="pubmed">35103413</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao Q., Xiong M., Li J., Hu H., Su H., Xu Y. Unraveling the catalytic mechanism of SARS-CoV-2 papain-like protease with allosteric modulation of C270 mutation using multiscale computational approaches. Chem. Sci. 2023;14:4681–4696. doi: 10.1039/D3SC00166K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D3SC00166K</ArticleId><ArticleId IdType="pmc">PMC10171076</ArticleId><ArticleId IdType="pubmed">37181765</ArticleId></ArticleIdList></Reference><Reference><Citation>Buller A.R., Townsend C.A. Intrinsic evolutionary constraints on protease structure, enzyme acylation, and the identity of the catalytic triad. Proc. Natl. Acad. Sci. USA. 2013;110:E653–E661. doi: 10.1073/pnas.1221050110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1221050110</ArticleId><ArticleId IdType="pmc">PMC3581919</ArticleId><ArticleId IdType="pubmed">23382230</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsässer B., Zauner F.B., Messner J., Soh W.T., Dall E., Brandstetter H. Distinct Roles of Catalytic Cysteine and Histidine in the Protease and Ligase Mechanisms of Human Legumain as Revealed by DFT-Based QM/MM Simulations. Acs Catal. 2017;7:5585–5593. doi: 10.1021/acscatal.7b01505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscatal.7b01505</ArticleId><ArticleId IdType="pmc">PMC5600538</ArticleId><ArticleId IdType="pubmed">28932620</ArticleId></ArticleIdList></Reference><Reference><Citation>McClain C.B., Vabret N. SARS-CoV-2: The many pros of targeting PLpro. Signal Transduct. Target. Ther. 2020;5:223. doi: 10.1038/s41392-020-00335-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00335-z</ArticleId><ArticleId IdType="pmc">PMC7537779</ArticleId><ArticleId IdType="pubmed">33024071</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H., Yang P., Zhang J. Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two birds with one stone. Front. Chem. 2022;10:822785. doi: 10.3389/fchem.2022.822785.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2022.822785</ArticleId><ArticleId IdType="pmc">PMC8905519</ArticleId><ArticleId IdType="pubmed">35281561</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia C.S.B., Lim S.P. A Patent Review on SARS Coronavirus Papain-Like Protease (PLpro) Inhibitors. Chemmedchem. 2023;18:e202300216. doi: 10.1002/cmdc.202300216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.202300216</ArticleId><ArticleId IdType="pubmed">37248169</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia C.S.B., Xu W., Ng P.S. A Patent Review on SARS Coronavirus Main Protease (3CLpro) Inhibitors. Chemmedchem. 2021;17:e202100576. doi: 10.1002/cmdc.202100576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.202100576</ArticleId><ArticleId IdType="pmc">PMC8653044</ArticleId><ArticleId IdType="pubmed">34651447</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh J., Petter R.C., Baillie T.A., Whitty A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 2011;10:307–317. doi: 10.1038/nrd3410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3410</ArticleId><ArticleId IdType="pubmed">21455239</ArticleId></ArticleIdList></Reference><Reference><Citation>Boike L., Henning N.J., Nomura D.K. Advances in covalent drug discovery. Nat. Rev. Drug Discov. 2022;21:881–898. doi: 10.1038/s41573-022-00542-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-022-00542-z</ArticleId><ArticleId IdType="pmc">PMC9403961</ArticleId><ArticleId IdType="pubmed">36008483</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F., Han X., Xiao X., Zhou J. Covalent Warheads Targeting Cysteine Residue: The promising approach in drug development. Molecules. 2022;27:7728. doi: 10.3390/molecules27227728.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27227728</ArticleId><ArticleId IdType="pmc">PMC9694382</ArticleId><ArticleId IdType="pubmed">36431829</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutanto F., Konstantinidou M., Dömling A. Covalent inhibitors: A rational approach to drug discovery. Rsc Med. Chem. 2020;11:876–884. doi: 10.1039/D0MD00154F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D0MD00154F</ArticleId><ArticleId IdType="pmc">PMC7557570</ArticleId><ArticleId IdType="pubmed">33479682</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer D., Cheng X. Recent Advances in Covalent Drug Discovery. Pharmaceuticals. 2023;16:663. doi: 10.3390/ph16050663.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16050663</ArticleId><ArticleId IdType="pmc">PMC10220821</ArticleId><ArticleId IdType="pubmed">37242447</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K.S., Quinn J.G., Saabye M.J., Guerrero J.F.S., Nonomiya J., Lian Q., Phung W., Izrayelit Y., Walters B.T., Gustafson A. High-Throughput Kinetic Characterization of Irreversible Covalent Inhibitors of KRASG12C by Intact Protein MS and Targeted MRM. Anal. Chem. 2022;94:1230–1239. doi: 10.1021/acs.analchem.1c04463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.analchem.1c04463</ArticleId><ArticleId IdType="pubmed">34990117</ArticleId></ArticleIdList></Reference><Reference><Citation>Mons E., Roet S., Kim R.Q., Mulder M.P.C. A Comprehensive Guide for Assessing Covalent Inhibition in Enzymatic Assays Illustrated with Kinetic Simulations. Curr. Protoc. 2022;2:e419. doi: 10.1002/cpz1.419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpz1.419</ArticleId><ArticleId IdType="pubmed">35671150</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins L.C., Oliveira R.B., Lameira J., Ferreira R.S. Experimental and Computational Study of Aryl-thiosemicarbazones Inhibiting Cruzain Reveals Reversible Inhibition and a Stepwise Mechanism. J. Chem. Inf. Model. 2023;63:1506–1520. doi: 10.1021/acs.jcim.2c01566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.2c01566</ArticleId><ArticleId IdType="pubmed">36802548</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves E.T.M., Pernichelle F.G., Nascimento L.A., Ferreira G.M., Ferreira E.I. Covalent Inhibitors for Neglected Diseases: An exploration of novel therapeutic options. Pharmaceuticals. 2023;16:1028. doi: 10.3390/ph16071028.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16071028</ArticleId><ArticleId IdType="pmc">PMC10385647</ArticleId><ArticleId IdType="pubmed">37513939</ArticleId></ArticleIdList></Reference><Reference><Citation>Brogi S., Ibba R., Rossi S., Butini S., Calderone V., Gemma S., Campiani G. Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent advancement in the field of viral and parasitic diseases. Molecules. 2022;27:2561. doi: 10.3390/molecules27082561.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27082561</ArticleId><ArticleId IdType="pmc">PMC9029279</ArticleId><ArticleId IdType="pubmed">35458759</ArticleId></ArticleIdList></Reference><Reference><Citation>Citarella A., Dimasi A., Moi D., Passarella D., Scala A., Piperno A., Micale N. Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From nirmatrelvir to future perspectives. Biomolecules. 2023;13:1339. doi: 10.3390/biom13091339.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom13091339</ArticleId><ArticleId IdType="pmc">PMC10647625</ArticleId><ArticleId IdType="pubmed">37759739</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami N., Hayden R., Hills T., Al-Samkari H., Casey J., del Sorbo L., Lawler P.R., Sise M.E., Leaf D.E. Therapeutic advances in COVID-19. Nat. Rev. Nephrol. 2022;19:38–52. doi: 10.1038/s41581-022-00642-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-022-00642-4</ArticleId><ArticleId IdType="pmc">PMC9574806</ArticleId><ArticleId IdType="pubmed">36253508</ArticleId></ArticleIdList></Reference><Reference><Citation>Halford B. The Path to Paxlovid. Acs Cent. Sci. 2022;8:405–407. doi: 10.1021/acscentsci.2c00369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.2c00369</ArticleId><ArticleId IdType="pmc">PMC9052793</ArticleId><ArticleId IdType="pubmed">35505871</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce R.P., Hu V.W., Wang J. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): An orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Med. Chem. Res. 2022;31:1637–1646. doi: 10.1007/s00044-022-02951-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00044-022-02951-6</ArticleId><ArticleId IdType="pmc">PMC9425786</ArticleId><ArticleId IdType="pubmed">36060104</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzi M., Vakil M.K., Bahmanyar M., Zarenezhad E. Paxlovid: Mechanism of action, synthesis, and in silico study. Biomed Res. Int. 2022;2022:7341493. doi: 10.1155/2022/7341493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/7341493</ArticleId><ArticleId IdType="pmc">PMC9283023</ArticleId><ArticleId IdType="pubmed">35845944</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy M.W. Paxlovid as a potential treatment for long COVID. Expert Opin. Pharmacother. 2023;24:1839–1843. doi: 10.1080/14656566.2023.2262387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2023.2262387</ArticleId><ArticleId IdType="pubmed">37731377</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemian S.M.R., Sheida A., Taghizadieh M., Memar M.Y., Hamblin M.R., Baghi H.B., Nahand J.S., Asemi Z., Mirzaei H. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to COVID-19 therapy? Biomed. Pharmacother. 2023;162:114367. doi: 10.1016/j.biopha.2023.114367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2023.114367</ArticleId><ArticleId IdType="pmc">PMC9899776</ArticleId><ArticleId IdType="pubmed">37018987</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W., Shao Y., Peng X., Liang B., Xu J., Xing D. Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection. Front. Pharmacol. 2022;13:1035969. doi: 10.3389/fphar.2022.1035969.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.1035969</ArticleId><ArticleId IdType="pmc">PMC9691842</ArticleId><ArticleId IdType="pubmed">36438815</ArticleId></ArticleIdList></Reference><Reference><Citation>Noske G.D., Silva E.S., Godoy M.O., Dolci I., Fernandes R.S., Guido R.V.C., Sjö P., Oliva G., Godoy A.S. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease. J. Biol. Chem. 2023;299:103004. doi: 10.1016/j.jbc.2023.103004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2023.103004</ArticleId><ArticleId IdType="pmc">PMC9916189</ArticleId><ArticleId IdType="pubmed">36775130</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper C.L., Van Heeswijk R.P.G., Gallicano K., Cameron D.W. A Review of Low-Dose Ritonavir in Protease Inhibitor Combination Therapy. Clin. Infect. Dis. 2003;36:1585–1592. doi: 10.1086/375233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/375233</ArticleId><ArticleId IdType="pubmed">12802760</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs J., Grum-Tokars V., Zhou Y., Turlington M., Saldanha S.A., Chase P., Eggler A., Dawson E.S., Baez-Santos Y.M., Tomar S. Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease. J. Med. Chem. 2013;56:534–546. doi: 10.1021/jm301580n.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm301580n</ArticleId><ArticleId IdType="pmc">PMC3569073</ArticleId><ArticleId IdType="pubmed">23231439</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma C., Xia Z., Sacco M.D., Hu Y., Townsend J.A., Meng X., Choza J., Tan H., Jang J., Gongora M.V. Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity. J. Am. Chem. Soc. 2021;143:20697–20709. doi: 10.1021/jacs.1c08060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.1c08060</ArticleId><ArticleId IdType="pmc">PMC8672434</ArticleId><ArticleId IdType="pubmed">34860011</ArticleId></ArticleIdList></Reference><Reference><Citation>Stille J.K., Tjutrins J., Wang G., Venegas F.A., Hennecker C., Rueda A.M., Sharon I., Blaine N., Miron C.E., Pinus S. Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors. Eur. J. Med. Chem. 2022;229:114046. doi: 10.1016/j.ejmech.2021.114046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2021.114046</ArticleId><ArticleId IdType="pmc">PMC8665847</ArticleId><ArticleId IdType="pubmed">34995923</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonatto V., Lameiro R.F., Rocho F.R., Lameira J., Leitão A., Montanari C.A. Nitriles: An attractive approach to the development of covalent inhibitors. Rsc Med. Chem. 2023;14:201–217. doi: 10.1039/D2MD00204C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D2MD00204C</ArticleId><ArticleId IdType="pmc">PMC9945868</ArticleId><ArticleId IdType="pubmed">36846367</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming F.F., Yao L., Ravikumar P.C., Funk L., Shook B.C. Nitrile-Containing Pharmaceuticals: Efficacious roles of the nitrile pharmacophore. J. Med. Chem. 2010;53:7902–7917. doi: 10.1021/jm100762r.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm100762r</ArticleId><ArticleId IdType="pmc">PMC2988972</ArticleId><ArticleId IdType="pubmed">20804202</ArticleId></ArticleIdList></Reference><Reference><Citation>Questel J.-Y.L., Berthelot M., Laurence C. Hydrogen-bond acceptor properties of nitriles: A combined crystallographic andab initio theoretical investigation. J. Phys. Org. Chem. 2000;13:347–358. doi: 10.1002/1099-1395(200006)13:6&lt;347::AID-POC251&gt;3.0.CO;2-E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1099-1395(200006)13:6&lt;347::AID-POC251&gt;3.0.CO;2-E</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Y., Jiang H., Wu W. Recent Advances in Chemical Modifications of Nitriles. Eur. J. Org. Chem. 2021;2021:6658–6669. doi: 10.1002/ejoc.202101196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejoc.202101196</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan B., Sacco M., Tan H., Li K., Joyce R., Zhang X., Chen Y., Wang J. Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors. Eur. J. Med. Chem. 2023;259:115667. doi: 10.1016/j.ejmech.2023.115667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2023.115667</ArticleId><ArticleId IdType="pmc">PMC10529912</ArticleId><ArticleId IdType="pubmed">37482021</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos M., Moreira R. Michael Acceptors as Cysteine Protease Inhibitors. Mini-Rev. Med. Chem. 2007;7:1040–1050. doi: 10.2174/138955707782110105.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138955707782110105</ArticleId><ArticleId IdType="pubmed">17979807</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H.W., Sethy B., Hsieh P.W., Horng J.T. Identification of Potential Drug Targets of Broad-Spectrum Inhibitors with a Michael Acceptor Moiety Using Shotgun Proteomics. Viruses. 2021;13:1756. doi: 10.3390/v13091756.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13091756</ArticleId><ArticleId IdType="pmc">PMC8473112</ArticleId><ArticleId IdType="pubmed">34578337</ArticleId></ArticleIdList></Reference><Reference><Citation>He J., Hu L., Huang X., Wang C., Zhang Z., Wang Y., Zhang D., Ye W. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors. Int. J. Antimicrob. Agents. 2020;56:106055. doi: 10.1016/j.ijantimicag.2020.106055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106055</ArticleId><ArticleId IdType="pmc">PMC7286838</ArticleId><ArticleId IdType="pubmed">32534187</ArticleId></ArticleIdList></Reference><Reference><Citation>Agost-Beltrán L., Lahoz-Rodríguez S., Bou-Iserte L., Rodríguez S., Fernández-de-La-Pradilla A., González F.V. Advances in the Development of SARS-CoV-2 Mpro Inhibitors. Molecules. 2022;27:2523. doi: 10.3390/molecules27082523.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27082523</ArticleId><ArticleId IdType="pmc">PMC9026863</ArticleId><ArticleId IdType="pubmed">35458721</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Xie W., Xue X., Yang K., Ma J., Liang W., Zhao Q., Zhou Z., Pei D., Ziebuhr J. Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases. PLoS Biol. 2005;3:324. doi: 10.1371/journal.pbio.0030324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0030324</ArticleId><ArticleId IdType="pmc">PMC1197287</ArticleId><ArticleId IdType="pubmed">16128623</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Chen C., Tan W., Yang K., Yang H. Structure of Main Protease from Human Coronavirus NL63: Insights for wide spectrum anti-coronavirus drug design. Sci. Rep. 2016;6:22677. doi: 10.1038/srep22677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep22677</ArticleId><ArticleId IdType="pmc">PMC4780191</ArticleId><ArticleId IdType="pubmed">26948040</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A.K., Gong G., Grum-Tokars V., Mulhearn D.C., Baker S.C., Coughlin M., Prabhakar B.S., Sleeman K., Johnson M.E., Mesecar A.D. Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors. Bioorg. Med. Chem. Lett. 2008;18:5684–5688. doi: 10.1016/j.bmcl.2008.08.082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2008.08.082</ArticleId><ArticleId IdType="pmc">PMC2745596</ArticleId><ArticleId IdType="pubmed">18796354</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A.K., Raghavaiah J., Shahabi D., Yadav M., Anson B.J., Lendy E.K., Hattori S.-I., Higashi-Kuwata N., Mitsuya H., Mesecar A.D. Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme inhibition, antiviral efficacy, structure-activity relationship, and x-ray structural studies. J. Med. Chem. 2021;64:14702–14714. doi: 10.1021/acs.jmedchem.1c01214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c01214</ArticleId><ArticleId IdType="pmc">PMC8457330</ArticleId><ArticleId IdType="pubmed">34528437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh A.K., Mishevich J.L., Mesecar A., Mitsuya H. Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 Infection and COVID-19. Chemmedchem. 2022;17:e202200440. doi: 10.1002/cmdc.202200440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.202200440</ArticleId><ArticleId IdType="pmc">PMC9538661</ArticleId><ArticleId IdType="pubmed">36165855</ArticleId></ArticleIdList></Reference><Reference><Citation>Maltarollo V.G., Silva E.B., Kronenberger T., Andrade M.M.S., Marques G.V.L., Oliveira N.J.C., Santos L.H., Rezende Júnior C.O., Martinho A.C.C., Skinner D. Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors. Future Med. Chem. 2023;15:959–985. doi: 10.4155/fmc-2023-0034.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc-2023-0034</ArticleId><ArticleId IdType="pubmed">37435731</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallari J.P., Shelat A., Kosinski A., Caffrey C.R., Connelly M., Zhu F., MCkerrow J.H., Guy R.K. Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorg. Med. Chem. Lett. 2008;18:2883–2885. doi: 10.1016/j.bmcl.2008.03.083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2008.03.083</ArticleId><ArticleId IdType="pmc">PMC2435229</ArticleId><ArticleId IdType="pubmed">18420405</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca N.C., Cruz L.F., Villela F.S., Pereira G.A.N., Siqueira-Neto J.L., Kellar D., Suzuki B.M., Ray D., Souza T.B., Alves R.J. Synthesis of a Sugar-Based Thiosemicarbazone Series and Structure-Activity Relationship versus the Parasite Cysteine Proteases Rhodesain, Cruzain, and Schistosoma mansoni Cathepsin B1. Antimicrob. Agents Chemother. 2015;59:2666–2677. doi: 10.1128/AAC.04601-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.04601-14</ArticleId><ArticleId IdType="pmc">PMC4394791</ArticleId><ArticleId IdType="pubmed">25712353</ArticleId></ArticleIdList></Reference><Reference><Citation>Dana D., Pathak S.K. A Review of Small Molecule Inhibitors and Functional Probes of Human Cathepsin L. Molecules. 2020;25:698. doi: 10.3390/molecules25030698.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25030698</ArticleId><ArticleId IdType="pmc">PMC7038230</ArticleId><ArticleId IdType="pubmed">32041276</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders B.C., Pokhrel S., Labbe A.D., Mathews I.I., Cooper C.J., Davidson R.B., Phillips G., Weiss K.L., Zhang Q., O’Neill H. Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2. Nat. Commun. 2023;14:1733. doi: 10.1038/s41467-023-37254-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37254-w</ArticleId><ArticleId IdType="pmc">PMC10044120</ArticleId><ArticleId IdType="pubmed">36977673</ArticleId></ArticleIdList></Reference><Reference><Citation>Maiti B.K. Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication? Acs Pharmacol. Transl. Sci. 2020;3:1017–1019. doi: 10.1021/acsptsci.0c00093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.0c00093</ArticleId><ArticleId IdType="pmc">PMC7409920</ArticleId><ArticleId IdType="pubmed">33062954</ArticleId></ArticleIdList></Reference><Reference><Citation>Rut W., Lv Z., Zmudzinski M., Patchett S., Nayak D., Snipas S.J., Oualid F.E., Huang T.T., Bekes M., Drag M. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design. Sci. Adv. 2020;6:eabd4596. doi: 10.1126/sciadv.abd4596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abd4596</ArticleId><ArticleId IdType="pmc">PMC7567588</ArticleId><ArticleId IdType="pubmed">33067239</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Z., Ratia K., Cooper L., Kong D., Lee H., Kwon Y., Li Y., Alqarni S., Huang F., Dubrovskyi O. Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity. J. Med. Chem. 2021;65:2940–2955. doi: 10.1021/acs.jmedchem.1c01307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c01307</ArticleId><ArticleId IdType="pmc">PMC8547495</ArticleId><ArticleId IdType="pubmed">34665619</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Chen G., He J., Li J., Xiong M., Su H., Li M., Hu H., Xu Y. Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease. Int. J. Mol. Sci. 2023;24:8633. doi: 10.3390/ijms24108633.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24108633</ArticleId><ArticleId IdType="pmc">PMC10218254</ArticleId><ArticleId IdType="pubmed">37239980</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratia K., Pegan S., Takayama J., Sleeman K., Coughlin M., Baliji S., Chaudhuri R., Fu W., Prabhakar B.S., Johnson M.E., et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl. Acad. Sci. USA. 2008;105:16119–16124. doi: 10.1073/pnas.0805240105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0805240105</ArticleId><ArticleId IdType="pmc">PMC2571001</ArticleId><ArticleId IdType="pubmed">18852458</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed Y.Y. Ensitrelvir Fumaric Acid: First approval. Drugs. 2024;84:721–728. doi: 10.1007/s40265-024-02039-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-024-02039-y</ArticleId><ArticleId IdType="pubmed">38795314</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M., Zeng X., Duan Y., Yang Z., Ma Y., Yang H., Yang X., Liu X. Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants. Commun. Biol. 2023;6:694. doi: 10.1038/s42003-023-05071-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-023-05071-y</ArticleId><ArticleId IdType="pmc">PMC10322880</ArticleId><ArticleId IdType="pubmed">37407698</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Wang T., Li M., Liu M., Tang H., Wang L., Ye K., Yang J., Jiang S., Xiao Y. Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 Mpro) Eur. J. Med. Chem. 2023;257:115487. doi: 10.1016/j.ejmech.2023.115487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2023.115487</ArticleId><ArticleId IdType="pmc">PMC10205138</ArticleId><ArticleId IdType="pubmed">37257212</ArticleId></ArticleIdList></Reference><Reference><Citation>Su H.-X., Yao S., Zhao W.-F., Li M.-J., Liu J., Shang W.-J., Xie H., Ke C.-Q., Hu H.-C., Gao M.-N. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol. Sin. 2020;41:1167–1177. doi: 10.1038/s41401-020-0483-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-020-0483-6</ArticleId><ArticleId IdType="pmc">PMC7393338</ArticleId><ArticleId IdType="pubmed">32737471</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q., Liu S., Zhou Y., Fan J., Ke S., Zhou Y., Fan K., Wang Y., Zhou Y., Xia Z. Discovery of meisoindigo derivatives as noncovalent and orally available Mpro inhibitors: Their therapeutic implications in the treatment of COVID-19. Eur. J. Med. Chem. 2024;273:116498. doi: 10.1016/j.ejmech.2024.116498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2024.116498</ArticleId><ArticleId IdType="pubmed">38762916</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y., Jin T., Zhang X., Zeng Z., Ye B., Wang J., Zhong Y., Xiong X., Gu L. Meisoindigo Protects Against Focal Cerebral Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Regulating Microglia/Macrophage Polarization via TLR4/NF-κB Signaling Pathway. Front. Cell. Neurosci. 2019;13:553. doi: 10.3389/fncel.2019.00553.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00553</ArticleId><ArticleId IdType="pmc">PMC6930809</ArticleId><ArticleId IdType="pubmed">31920554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegethoff J., Bischoff R., Saleh S., Blagojevic B., Merz K.-H., Cheng X. Methylisoindigo and Its Bromo-Derivatives Are Selective Tyrosine Kinase Inhibitors, Repressing Cellular Stat3 Activity, and Target CD133+ Cancer Stem Cells in PDAC. Molecules. 2017;22:1546. doi: 10.3390/molecules22091546.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules22091546</ArticleId><ArticleId IdType="pmc">PMC6151689</ArticleId><ArticleId IdType="pubmed">32961646</ArticleId></ArticleIdList></Reference><Reference><Citation>Barretto N., Jukneliene D., Ratia K., Chen Z., Mesecar A.D., Baker S.C. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J. Virol. 2005;79:15189–15198. doi: 10.1128/JVI.79.24.15189-15198.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.24.15189-15198.2005</ArticleId><ArticleId IdType="pmc">PMC1316023</ArticleId><ArticleId IdType="pubmed">16306590</ArticleId></ArticleIdList></Reference><Reference><Citation>Garland O., Ton A.T., Moradi S., Smith J.R., Kovacic S., Ng K., Pandey M., Ban F., Lee J., Vuckovic M., et al. Large-Scale Virtual Screening for the Discovery of SARS-CoV-2 Papain-like Protease (PLpro) Non-covalent Inhibitors. J. Chem. Inf. Model. 2023;63:2158–2169. doi: 10.1021/acs.jcim.2c01641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jcim.2c01641</ArticleId><ArticleId IdType="pubmed">36930801</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman R.L., Kania R.S., Brothers M.A., Davies J.F., Ferre R.A., Gajiwala K.S., He M., Hogan R.J., Kozminski K., Li L.Y. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. J. Med. Chem. 2020;63:12725–12747. doi: 10.1021/acs.jmedchem.0c01063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c01063</ArticleId><ArticleId IdType="pmc">PMC7571312</ArticleId><ArticleId IdType="pubmed">33054210</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Wang J., Wang S., Yue K., Hu Y., Liu X., Wang L., Wan S., Xu X. Discovery of new non-covalent and covalent inhibitors targeting SARS-CoV-2 papain-like protease and main protease. Bioorg. Chem. 2023;140:106830. doi: 10.1016/j.bioorg.2023.106830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioorg.2023.106830</ArticleId><ArticleId IdType="pubmed">37683544</ArticleId></ArticleIdList></Reference><Reference><Citation>Sargsyan K., Lin C.-C., Chen T., Grauffel C., Chen Y.-P., Yang W.-Z., Liang J.-J., Lian C.-C., Lin Y.-L., Yuan H.S. Correction: Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe zn-ejectors. Chem. Sci. 2021;12:6210. doi: 10.1039/D1SC90081A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1SC90081A</ArticleId><ArticleId IdType="pmc">PMC8098677</ArticleId><ArticleId IdType="pubmed">33999042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X., Su H., Shang W., Zhou F., Zhang Y., Zhao W., Zhang Q., Xie H., Jiang L., Nie T. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. Nat. Commun. 2023;14:6463. doi: 10.1038/s41467-023-42102-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-42102-y</ArticleId><ArticleId IdType="pmc">PMC10575921</ArticleId><ArticleId IdType="pubmed">37833261</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X.-M., Yang Y., Yao B.-F., Ye P.-P., Xu Y., Peng S.-P., Yang Y.-M., Shu P., Li P.-J., Li S. A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects. Eur. J. Pharm. Sci. 2023;191:106598. doi: 10.1016/j.ejps.2023.106598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2023.106598</ArticleId><ArticleId IdType="pubmed">37783378</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu K.-W. Deuremidevir and Simnotrelvir–Ritonavir for the Treatment of COVID-19. Acs Pharmacol. Transl. Sci. 2023;6:1306–1309. doi: 10.1021/acsptsci.3c00134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsptsci.3c00134</ArticleId><ArticleId IdType="pmc">PMC10496140</ArticleId><ArticleId IdType="pubmed">37705591</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilby K.J., Partovi N., Ford J.-A., Greanya E.D., Yoshida E.M. Review of Boceprevir and Telaprevir for the Treatment of Chronic Hepatitis C. Can. J. Gastroenterol. 2012;26:205–210. doi: 10.1155/2012/751057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/751057</ArticleId><ArticleId IdType="pmc">PMC3354889</ArticleId><ArticleId IdType="pubmed">22506260</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Xiao W., Tang Y., Cao M., Shu D., Asakawa T., Xu Y., Jiang X., Zhang L., Wang W. Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: A randomised, double-blind, placebo-controlled, phase 1b trial. Lancet Reg. Health—West. Pac. 2023;38:100835. doi: 10.1016/j.lanwpc.2023.100835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2023.100835</ArticleId><ArticleId IdType="pmc">PMC10362366</ArticleId><ArticleId IdType="pubmed">37484496</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B., Wang Y., Lu H., Huang C., Yang Y., Shang L., Chen Z., Jiang R., Liu Y., Lin L., et al. Oral Simnotrelvir for Adult Patients with Mild-to-Moderate COVID-19. N. Engl. J. Med. 2024;390:230–241. doi: 10.1056/NEJMoa2301425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2301425</ArticleId><ArticleId IdType="pmc">PMC11156186</ArticleId><ArticleId IdType="pubmed">38231624</ArticleId></ArticleIdList></Reference><Reference><Citation>Zagórska A., Czopek A., Fryc M., Jończyk J. Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents. Biomolecules. 2024;14:797. doi: 10.3390/biom14070797.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom14070797</ArticleId><ArticleId IdType="pmc">PMC11275247</ArticleId><ArticleId IdType="pubmed">39062511</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>